Company profile

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Privately held: no public share price (AML registry sponsor; ownership/ticker not yet curated.)

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Foritinib succinate
Phase 3
ALK / ROS1Small molecule
Non-Small Cell Lung Cancer
FCN-338
Phase 2
BCL-2Small molecule
Acute Myeloid Leukemia
Luvometinib
Phase 2
MEK1/2
Non-Small Cell Lung Cancer
FXS0683
Phase 1
BCL-2
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.